Merus/MRUS

$47.60

0.31%
-
1D1W1MYTD1YMAX

About Merus

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Ticker

MRUS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sven Lundberg

Employees

164

Headquarters

Utrecht, Netherlands
Website
merus.nl

Merus Metrics

BasicAdvanced
$2.74B
Market cap
-
P/E ratio
-$3.72
EPS
1.12
Beta
-
Dividend rate

What the Analysts think about Merus

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 11 analysts.
4.71% downside
High $56.00
Low $40.00
$47.60
Current price
$45.36
Average price target

Merus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-209.09% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$11M
5.77%
Net income
$-23M
-28.13%
Profit margin
-209.09%
-32.05%

Merus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 41.37%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.81
-$0.86
-$0.66
-$0.43
-
Expected
-$0.83
-$1.02
-$0.88
-$0.73
-$0.74
Surprise
119.25%
-15.54%
-24.62%
-41.37%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Merus stock

Buy or sell Merus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing